Natacha Omer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natacha Omer has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Paul G. Ekert
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
4 shared publications Ashleigh Sullivan
Oncology Service, Children’s Health Queensland Hospital & Health Service
3 shared publications- Chelsea Mayoh
Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, Australia
3 shared publications - David S. Ziegler
Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia
3 shared publications - Loretta M. S. Lau
Sydney Children's Hospital
3 shared publications - Marie Wong
Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, Australia
3 shared publications
Latest Publications
- Open Access
- 17 July 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (10) , 1582-1588
The Use of a Ward Round Teaching Tool in a Paediatric Oncology Department
Aim: Despite ward rounds being fundamental to hospital‐based clinical training, the reported educational value is low. Especially in busy environments, missed learning opportunities occur due to implicit learning, time barriers, and lack of ward round structure. The STIC framework ( S et, T arget, I nspect, Close ) provides a learner‐centred, structured approach to ward round teaching, aimed to enhance education within limited timeframes. We aimed to investigate how the introduction of the STIC framework impacts on learner‐centred teaching within a tertiary Paediatric Oncology department. Methods: A mixed‐methods approach was used to evaluate framework implementation, with two participant groups comprising 16 junior and senior doctors over 3 months. Surveys were used to document junior staff experience on rounds pre‐ and post‐implementation, with focus groups and interviews used for all participants to explore satisfaction and attitudes to the tool. Results: Learner satisfaction improved across all domains of the framework, specifically opportunities for leading clinical encounters and learning on consultant‐led rounds. Despite consultants reporting lack of uptake, trainees reported improved teaching. Consultant beliefs and enthusiasm had a strong impact on trainee satisfaction. Trainees placed a high value on active participation and autonomy for their learning. Factors distinct to teaching were reported to affect learner satisfaction, such as planning, time management, and departmental culture. Conclusions: We demonstrate enhanced teaching despite poor perceived uptake, demonstrating the potential of the STIC framework with further implementation. Our study also highlights that in addition to a specific teaching focus, consultant engagement and a safe clinical learning environment are crucial for learning.
- 17 July 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (10) , 1582-1588
Open AccessThe Use of a Ward Round Teaching Tool in a Paediatric Oncology Department
Aim: Despite ward rounds being fundamental to hospital‐based clinical training, the reported educational value is low. Especially in busy environments, missed learning opportunities occur due to implicit learning, time barriers, and lack of ward round structure. The STIC framework ( S et, T arget, I nspect, Close ) provides a learner‐centred, structured approach to ward round teaching, aimed to enhance education within limited timeframes. We aimed to investigate how the introduction of the STIC framework impacts on learner‐centred teaching within a tertiary Paediatric Oncology department. Methods: A mixed‐methods approach was used to evaluate framework implementation, with two participant groups comprising 16 junior and senior doctors over 3 months. Surveys were used to document junior staff experience on rounds pre‐ and post‐implementation, with focus groups and interviews used for all participants to explore satisfaction and attitudes to the tool. Results: Learner satisfaction improved across all domains of the framework, specifically opportunities for leading clinical encounters and learning on consultant‐led rounds. Despite consultants reporting lack of uptake, trainees reported improved teaching. Consultant beliefs and enthusiasm had a strong impact on trainee satisfaction. Trainees placed a high value on active participation and autonomy for their learning. Factors distinct to teaching were reported to affect learner satisfaction, such as planning, time management, and departmental culture. Conclusions: We demonstrate enhanced teaching despite poor perceived uptake, demonstrating the potential of the STIC framework with further implementation. Our study also highlights that in addition to a specific teaching focus, consultant engagement and a safe clinical learning environment are crucial for learning.
- Open Access
Expanding the utility of transcriptome analysis for mutation detection in high-risk childhood precision oncology
In precision oncology, whole transcriptome sequencing (RNA-seq) excels at identifying oncogenic fusions. Here, using a cohort of 477 high-risk paediatric tumours, we demonstrate that RNA-seq can identify all mutation classes found previously using whole genome sequencing (WGS) and provides additional functional insights into their pathogenicity. By incorporating reference-guided fusion, and reference-free structural variant (SV) detection algorithms with RNA abundance assessment, RNA-seq identified 96% of SVs and resolved 33 complex SVs that WGS failed to identify. Furthermore, RNA-seq identified 92% of all single nucleotide variants and small insertions and deletions. Importantly RNA-seq informed the pathogenicity assessment in 22% of variants through identification of allele specific expression or the functional consequence of splice-altering variants. The utility of RNA-seq extends beyond fusion identification to the interpretation of mutation pathogenicity and the discovery of important mutations that would otherwise go undetected. We propose that RNA-seq is an indispensable companion to WGS in precision medicine.
Open AccessExpanding the utility of transcriptome analysis for mutation detection in high-risk childhood precision oncology
In precision oncology, whole transcriptome sequencing (RNA-seq) excels at identifying oncogenic fusions. Here, using a cohort of 477 high-risk paediatric tumours, we demonstrate that RNA-seq can identify all mutation classes found previously using whole genome sequencing (WGS) and provides additional functional insights into their pathogenicity. By incorporating reference-guided fusion, and reference-free structural variant (SV) detection algorithms with RNA abundance assessment, RNA-seq identified 96% of SVs and resolved 33 complex SVs that WGS failed to identify. Furthermore, RNA-seq identified 92% of all single nucleotide variants and small insertions and deletions. Importantly RNA-seq informed the pathogenicity assessment in 22% of variants through identification of allele specific expression or the functional consequence of splice-altering variants. The utility of RNA-seq extends beyond fusion identification to the interpretation of mutation pathogenicity and the discovery of important mutations that would otherwise go undetected. We propose that RNA-seq is an indispensable companion to WGS in precision medicine.
- Top Cited PapersOpen Access
- 6 June 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1913-1922
Precision-guided treatment in high-risk pediatric cancers
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here we report consecutive data from 384 patients with high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial. A total of 256 (67%) patients received PGT recommendations and 110 (29%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% versus 12%; P = 0.049) or targeted agents not guided by molecular findings (26% versus 5.2%; P = 0.003). PGT based on tier 1 evidence, PGT targeting fusions or commenced before disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers. ClinicalTrials.gov registration: NCT03336931
- 6 June 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1913-1922
Top Cited PapersOpen AccessPrecision-guided treatment in high-risk pediatric cancers
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here we report consecutive data from 384 patients with high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial. A total of 256 (67%) patients received PGT recommendations and 110 (29%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% versus 12%; P = 0.049) or targeted agents not guided by molecular findings (26% versus 5.2%; P = 0.003). PGT based on tier 1 evidence, PGT targeting fusions or commenced before disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers. ClinicalTrials.gov registration: NCT03336931
- Open Access
- 3 October 2023
- Published by Springer Nature in Research Square
Precision-guided treatment improves outcomes for children with high-risk cancers
Recent reports have shown that precision medicine can identify new treatment strategies for childhood cancer patients. However, it remains unclear which patients will benefit most from precision-guided treatment (PGT). Here we report 384 consecutive high-risk childhood cancer patients (with an expected cure rate of <30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Program PRISM trial. A total of 256 (67%) patients received PGT recommendations, of whom 110 (43%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% vs. 12%; P=0.049) or targeted agents not guided by molecular findings (26% vs. 5.2%; P=0.003). PGT based on Tier 1 evidence, PGT targeting fusions or commenced prior to disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers.
- 3 October 2023
- Published by Springer Nature in Research Square
Open AccessPrecision-guided treatment improves outcomes for children with high-risk cancers
Recent reports have shown that precision medicine can identify new treatment strategies for childhood cancer patients. However, it remains unclear which patients will benefit most from precision-guided treatment (PGT). Here we report 384 consecutive high-risk childhood cancer patients (with an expected cure rate of <30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Program PRISM trial. A total of 256 (67%) patients received PGT recommendations, of whom 110 (43%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% vs. 12%; P=0.049) or targeted agents not guided by molecular findings (26% vs. 5.2%; P=0.003). PGT based on Tier 1 evidence, PGT targeting fusions or commenced prior to disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers.
- Open Access
- 30 November 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1798
Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
Despite aggressive surgery, chemotherapy, and radiotherapy, survival of children and adolescents and young adults (AYAs) with sarcoma has not improved significantly in the past four decades. Immune checkpoint inhibitors (ICIs) are an exciting type of immunotherapy that offer new opportunities for the treatment of paediatric and AYA sarcomas. However, to date, most children do not derive a benefit from this type of treatment as a monotherapy. The immunosuppressive tumour microenvironment is a major barrier limiting their efficacy. Combinations of ICIs, such as anti-PD-1 therapy, with targeted molecular therapies that have immunomodulatory properties may be the key to breaking through immunosuppressive barriers and improving patient outcomes. Preclinical studies have indicated that several receptor tyrosine kinase inhibitors (RTKi) can alter the tumour microenvironment and boost the efficacy of anti-PD-1 therapy. A number of these combinations have entered phase-1/2 clinical trials, mostly in adults, and in most instances have shown efficacy with manageable side-effects. In this review, we discuss the status of ICI therapy in paediatric and AYA sarcomas and the rationale for co-treatment with RTKis. We highlight new opportunities for the integration of ICI therapy with RTK inhibitors, to improve outcomes for children with sarcoma.
- 30 November 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1798
Open AccessEnhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
Despite aggressive surgery, chemotherapy, and radiotherapy, survival of children and adolescents and young adults (AYAs) with sarcoma has not improved significantly in the past four decades. Immune checkpoint inhibitors (ICIs) are an exciting type of immunotherapy that offer new opportunities for the treatment of paediatric and AYA sarcomas. However, to date, most children do not derive a benefit from this type of treatment as a monotherapy. The immunosuppressive tumour microenvironment is a major barrier limiting their efficacy. Combinations of ICIs, such as anti-PD-1 therapy, with targeted molecular therapies that have immunomodulatory properties may be the key to breaking through immunosuppressive barriers and improving patient outcomes. Preclinical studies have indicated that several receptor tyrosine kinase inhibitors (RTKi) can alter the tumour microenvironment and boost the efficacy of anti-PD-1 therapy. A number of these combinations have entered phase-1/2 clinical trials, mostly in adults, and in most instances have shown efficacy with manageable side-effects. In this review, we discuss the status of ICI therapy in paediatric and AYA sarcomas and the rationale for co-treatment with RTKis. We highlight new opportunities for the integration of ICI therapy with RTK inhibitors, to improve outcomes for children with sarcoma.
- Open Access
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma
Sarcomas are a diverse group of bone and soft tissue tumors that account for over 10% of childhood cancers. Outcomes are particularly poor for children with refractory, relapsed, or metastatic disease. Chimeric antigen receptor T (CAR T) cells are an exciting form of adoptive cell therapy that potentially offers new hope for these children. In early trials, promising outcomes have been achieved in some pediatric patients with sarcoma. However, many children do not derive benefit despite significant expression of the targeted tumor antigen. The success of CAR T cell therapy in sarcomas and other solid tumors is limited by the immunosuppressive tumor microenvironment (TME). In this review, we provide an update of the CAR T cell therapies that are currently being tested in pediatric sarcoma clinical trials, including those targeting tumors that express HER2, NY-ESO, GD2, EGFR, GPC3, B7-H3, and MAGE-A4. We also outline promising new CAR T cells that are in pre-clinical development. Finally, we discuss strategies that are being used to overcome tumor-mediated immunosuppression in solid tumors; these strategies have the potential to improve clinical outcomes of CAR T cell therapy for children with sarcoma.
Open AccessChimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma
Sarcomas are a diverse group of bone and soft tissue tumors that account for over 10% of childhood cancers. Outcomes are particularly poor for children with refractory, relapsed, or metastatic disease. Chimeric antigen receptor T (CAR T) cells are an exciting form of adoptive cell therapy that potentially offers new hope for these children. In early trials, promising outcomes have been achieved in some pediatric patients with sarcoma. However, many children do not derive benefit despite significant expression of the targeted tumor antigen. The success of CAR T cell therapy in sarcomas and other solid tumors is limited by the immunosuppressive tumor microenvironment (TME). In this review, we provide an update of the CAR T cell therapies that are currently being tested in pediatric sarcoma clinical trials, including those targeting tumors that express HER2, NY-ESO, GD2, EGFR, GPC3, B7-H3, and MAGE-A4. We also outline promising new CAR T cells that are in pre-clinical development. Finally, we discuss strategies that are being used to overcome tumor-mediated immunosuppression in solid tumors; these strategies have the potential to improve clinical outcomes of CAR T cell therapy for children with sarcoma.
- 1 April 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 75, 98-108
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience
- 1 April 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 75, 98-108
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience